Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NVS

Novartis AG ADR

Apr 18 • 04:00PM ET

92.57

Dollar change -0.51
Percentage change -0.55	%

Healthcare • Drug Manufacturers - General • Switzerland • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	12.96	EPS (ttm)	7.14	Insider Own	0.00%	Shs Outstand	2.04B	Perf Week	-1.88%
Market Cap	181.11B	Forward P/E	12.00	EPS next Y	7.71	Insider Trans	-	Shs Float	1.96B	Perf Month	-3.89%
Income	14.85B	PEG	1.94	EPS next Q	1.67	Inst Own	7.27%	Short Float	0.22%	Perf Quarter	-14.31%
Sales	49.78B	P/S	3.64	EPS this Y	9.37%	Inst Trans	-9.01%	Short Ratio	2.82	Perf Half Y	-4.06%
Book/sh	22.83	P/B	4.05	EPS next Y	9.02%	ROA	7.76%	Short Interest	4.21M	Perf Year	0.52%
Cash/sh	7.37	P/C	12.55	EPS next 5Y	6.68%	ROE	16.52%	52W Range	88.86 - 108.78	Perf YTD	-8.32%
Dividend Est.	3.62 (3.91%)	P/FCF	13.52	EPS past 5Y	5.63%	ROI	22.26%	52W High	-14.90%	Beta	0.55
Dividend TTM	3.74 (4.04%)	Quick Ratio	0.93	Sales past 5Y	0.78%	Gross Margin	70.87%	52W Low	4.17%	ATR (14)	1.29
Dividend Ex-Date	Mar 07, 2024	Current Ratio	1.16	EPS Y/Y TTM	125.94%	Oper. Margin	26.06%	RSI (14)	33.12	Volatility	1.01% 0.92%
Employees	76057	Debt/Eq	0.56	Sales Y/Y TTM	-1.51%	Profit Margin	29.83%	Recom	2.56	Target Price	109.59
Option/Short	Yes / Yes	LT Debt/Eq	0.43	EPS Q/Q	502.21%	Payout	44.73%	Rel Volume	0.61	Prev Close	93.08
Sales Surprise	-3.88%	EPS Surprise	-7.31%	Sales Q/Q	-9.98%	Earnings	Apr 23 BMO	Avg Volume	1.49M	Price	92.57
SMA20	-2.74%	SMA50	-6.12%	SMA200	-5.58%	Trades		Volume	906,388	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform
Sep-14-22	Downgrade	Berenberg	Buy → Hold
May-09-22	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-22	Resumed	Citigroup	Buy
Dec-14-21	Downgrade	Redburn	Buy → Neutral
Dec-06-21	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-03-21	Downgrade	Bryan Garnier	Buy → Neutral
Sep-20-21	Downgrade	Deutsche Bank	Hold → Sell
Mar-22-21	Initiated	Bernstein	Mkt Perform
Mar-10-21	Downgrade	Argus	Buy → Hold

Show Previous Ratings

Today 06:33PM	US FDA mandates label updates on CAR-T cancer therapies (Reuters)
09:15AM	Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-17-24 09:30AM	2 High-Yield Dividend Stocks to Buy and Hold for 10 Years (Motley Fool)
01:15AM	Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis (GlobeNewswire)
Apr-16-24 09:06AM	Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug (Zacks)
02:00PM	Loading…
Apr-15-24 02:00PM	New Novartis Fabhalta (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) (PR Newswire)
04:46AM	Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining. (Yahoo Finance)
Apr-12-24 01:55PM	Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate (Zacks)
08:53AM	NICE recommends Novartis' CAR-T therapy for leukaemia (Pharmaceutical Business Review)
06:26AM	Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing (FierceBiotech.com)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
11:27AM	Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials (Quartz)
09:45AM	Novartis (NVS) to Undertake Job Cuts in Development Department (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
08:06AM	Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader (FierceBiotech.com)
07:40AM	Loading…
07:40AM	UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion (Reuters)
07:17AM	Novartis licenses Arvinas' cancer drug for up to $1 billion (Reuters)
07:00AM	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer (GlobeNewswire)
04:39AM	UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys (Reuters)
04:20AM	Novartis tender offer for MorphoSys AG commences (GlobeNewswire)
Apr-10-24 10:12AM	Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts (InvestorPlace)
08:11AM	Novartis pauses some trials of cancer drug Kisqali to fix manufacturing (BioPharma Dive)
08:11AM	Novartis pauses enrollment in some Kisqali trials to fix manufacturing (BioPharma Dive)
Apr-09-24 10:15AM	Novartis to cut 680 jobs in product development (Reuters)
Apr-06-24 04:16PM	New Novartis data show early addition of twice-yearly* Leqvio (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting (PR Newswire)
Apr-05-24 06:00PM	Novartis (NVS) Stock Sinks As Market Gains: Here's Why (Zacks)
Apr-04-24 03:42PM	Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study (Investopedia)
Apr-03-24 08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
Apr-02-24 06:15PM	Novartis (NVS) Declines More Than Market: Some Information for Investors (Zacks)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
04:56PM	Loading…
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-31-24 04:34PM	25 Countries with Highest Malaria Death Rates (Insider Monkey)
Mar-30-24 03:52PM	11 Oversold Blue Chip Stocks to Buy Right Now (Insider Monkey)
Mar-29-24 05:02PM	15 Biggest Swiss Companies (Insider Monkey)
Mar-28-24 09:00AM	Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know (Zacks)
Mar-27-24 06:00PM	Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
Mar-26-24 01:06PM	Harnessing AI for Drug Discovery: Top 3 Stocks to Watch (InvestorPlace)
07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
06:18AM	25 Countries with the Highest Death Rate From Malnutrition (Insider Monkey)
Mar-25-24 06:15PM	Novartis (NVS) Declines More Than Market: Some Information for Investors (Zacks)
12:58PM	30 Countries with Highest Proportion of Older Adults (Insider Monkey)
07:26AM	EMA CHMP recommends marketing authorisation for Novartis' PNH treatment (Pharmaceutical Business Review)
Mar-24-24 10:40AM	5 Most Undervalued Large-Cap Stocks To Buy According To Analysts (Insider Monkey)
08:15AM	1 Magnificent Dividend Stock to Buy and Hold (Motley Fool)
Mar-22-24 07:22AM	Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)
Mar-19-24 06:00PM	Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
Mar-18-24 06:15PM	Novartis (NVS) Stock Dips While Market Gains: Key Facts (Zacks)
01:28PM	US appeals court revives Regeneron's antitrust lawsuit against Novartis (Reuters)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
09:00AM	Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock (Zacks)
08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-13-24 09:02AM	Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront (FierceBiotech.com)
07:08AM	IFM, an unorthodox biotech startup, scores third buyout with Novartis deal (BioPharma Dive)
Mar-12-24 06:00PM	Novartis (NVS) Stock Dips While Market Gains: Key Facts (Zacks)
Mar-11-24 06:15PM	Novartis (NVS) Advances While Market Declines: Some Information for Investors (Zacks)
12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-10-24 06:35AM	3 Dividend Stocks to Buy Hand Over Fist in March (Motley Fool)
Mar-06-24 05:01AM	Novartis AG's Dividend Analysis (GuruFocus.com)
Mar-05-24 06:00PM	Novartis (NVS) Gains As Market Dips: What You Should Know (Zacks)
09:22AM	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
02:56AM	13 Best Pharma Dividend Stocks To Buy in 2024 (Insider Monkey)
Mar-04-24 01:15AM	Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA (GlobeNewswire)
Mar-01-24 03:10PM	3 Stocks Primed for Exponential Returns by 2034 (InvestorPlace)
09:00AM	Is Trending Stock Novartis AG (NVS) a Buy Now? (Zacks)
Feb-29-24 08:30AM	2 Dividend Stocks to Buy and Hold Forever (Motley Fool)
Feb-28-24 06:00PM	Here's Why Novartis (NVS) Fell More Than Broader Market (Zacks)
10:27AM	No ongoing sale process at Cytokinetics, CEO says following Novartis acquisition rumors (FierceBiotech.com)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-23-24 05:43AM	20 Fastest Growing Biotech Companies in the US (Insider Monkey)
Feb-22-24 09:21AM	GRAPHIC-Drugs, fashion and chips - the STOXX 600's 'Magnificent 4' (Reuters)
Feb-15-24 04:13PM	7 Contrarian Biotech Stocks to Consider Amid Sector Weakness (InvestorPlace)
Feb-14-24 03:21PM	30 Countries with Highest Standard of Living Ranked by GDP (PPP) Per Capita (Insider Monkey)
08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
Feb-10-24 08:30AM	30 Most Valuable Drug Companies in 2024 (Insider Monkey)
Feb-06-24 11:16AM	Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug (Zacks)
10:29AM	Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline (Investopedia)
04:30AM	MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte (BioPharma Dive)
04:23AM	Novartis Buys MorphoSys for 2.7 Billion to Get Cancer Drugs (Bloomberg)
01:40AM	PRESS DIGEST- Wall Street Journal - Feb 6 (Reuters)
Feb-05-24 06:54PM	Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion (Investor's Business Daily)
06:47PM	Analyst Report: Novartis AG (Morningstar Research)
06:35PM	UPDATE 3-Novartis to acquire cancer-focused MorphoSys for $2.9 bln (Reuters)
05:44PM	Novartis acquiring cancer drug developer Morphosys for 2.7 billion (CNBC TV)
05:30PM	Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H (The Wall Street Journal)
04:55PM	Novartis to acquire cancer-focused MorphoSys for $2.9 billion (Reuters)
04:52PM	REFILE-Novartis acquires cancer drug developer MorphoSys for $2.9 bln (Reuters)
04:45PM	Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash (GlobeNewswire)
Feb-04-24 05:50AM	3 Fabulous Dividend Stocks to Buy in February (Motley Fool)
Feb-02-24 08:52AM	Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments (FierceBiotech.com)
Feb-01-24 01:23PM	Novartis CEO Vasant Narasimhan on Q4 earnings miss (CNBC TV)
11:55AM	Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Jan-31-24 04:05PM	Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short. (Investor's Business Daily)
03:56PM	Novartis CEO explains 'prudent' 2024 guidance (Yahoo Finance Video)
02:30PM	Novartis Ag (NVS) Q4 2023 Earnings Call Transcript (Motley Fool)
01:50PM	Novartis Stock Slumps After Drugmaker's Earnings, Guidance Fall Short of Expectations (Investopedia)
12:50PM	Novo Nordisk Tops $500 Billion Valuation; Ozempic, Wegovy Fuel Earnings (The Wall Street Journal)
11:47AM	Analyst Report: Novartis AG (Morningstar Research)
11:00AM	Novo Nordisk Earnings Top Forecasts, Fueled by Ozempic, Wegovy Sales (The Wall Street Journal)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your FINVIZ experience